Elotuzumab - Bristol-Myers Squibb

Drug Profile

Elotuzumab - Bristol-Myers Squibb

Alternative Names: BMS-901608; Empliciti; HuLuc63; PDL063

Latest Information Update: 12 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PDL BioPharma
  • Developer AbbVie; Australasian Leukaemia & Lymphoma Group; Bristol-Myers Squibb
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Surface antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma

Most Recent Events

  • 06 Nov 2018 The US FDA approves sBLA for elotuzumab with pomalidomide and low-dose dexamethasone for Multiple myeloma
  • 06 Nov 2018 Updated efficacy and adverse events data from the phase II ELOQUENT-3 trial in Multiple myeloma released by Bristol-Myers Squibb
  • 18 Sep 2018 The EMA validates type II variation application for Elotuzumab in combination with pomalidomide and low-dose dexamethasone for Multiple myeloma (Second-line therapy or greater) for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top